Robust Pipeline Across Multiple Therapeutic Areas

Kaleido is advancing a robust pipeline of Microbiome Metabolic Therapies (MMTs) across a range of therapeutic areas, including candidates that have advanced to clinical testing.

table

Discovery & Development Model

At Kaleido, we are breaking the mold of traditional therapeutic product development. We are redefining traditional R&D with our unique discovery and development model that enables product candidates to advance rapidly into the clinic. This model results in early and continuous integration of human data and higher translatability between what is observed ex vivo and in vivo.